ANTI- ANGINAL DRUGS
Anti anginal drugs
 Angina pectoris
 Types
 Classification
 Nitrates
 Calcium channel
blockers
 blockers
 Combination therapy


CONTENT
ANTI-ANGINAL DRUGS








Antianginal drugs may relieve attacks of acute myocardial
ischemia by increasing myocardial oxygen supply
or by decreasing myocardial oxygen demand
Three groups of pharmacological agents have
been shown to be effective in reducing the frequency,
severity, or both of primary or secondary angina.
These agents include the nitrates, adrenoceptor
antagonists,
and calcium entry blockers.
To understand the beneficial actions of these agents, it is
important
to be familiar with the major factors regulating
the balance between
ANGINA PECTORIS
It is the principal symptoms of patient with
ischemic heart disease.
 Manifested by sudden, severe, pressing
substernal pain that often radiates to the left
shoulder and along the flexor surface of the
left arm.
 Usually precipitated by exercise, excitement
or a heavy meal.

Anti  anginal drugs ppt by anjali kotwal
TYPES OF ANGINA PECTORIS
Anti  anginal drugs ppt by anjali kotwal
Anti  anginal drugs ppt by anjali kotwal
Anti  anginal drugs ppt by anjali kotwal
NITRATES
Classification of nitrates:
1. Rapidly acting nitrates
* used to terminate acute attack of angina
* e.g.- Nitroglycerin and Amyl nitrate
* usually administered sublingually
2.

Long acting nitrates
* used to prevent an attack of angina
* e.g. – tetra nitrate, Iso sorbide di
nitrate, Penta erythrytol tetra nitrate
* administered orally or topically







Organic nitrates & nitrites are
simple nitric & nitrous esters of
glycerol.
These agents cause a rapid
decrease in myocardial oxygen
demand leading to rapid
resolution of symptoms.
Nitrates are effective for all
types of angina.
Activation of guanylate cyclase
increases cGMP activating a
cGMP kinase leading to
dephosphorylation of myosin
light chains decreasing
contractile force.

ORGANIC NITRATES
Anti  anginal drugs ppt by anjali kotwal
1ST MECHANISM OF ACTION
Coronary artery dilatation
Decrease coronary bed resistance
(Relieved coronary vasospasm)

Increase coronary blood flow

Increase oxygen supply
2ND MECHANISM OF ACTION
Reduction on peripheral resistance
(Secondary to dilatation of aorta)

Decrease blood pressure

Decrease after load
Decrease workload
Decrease oxygen consumption
3RD MECHANISM OF ACTION
Reduced venous return
(Due to dilatation of the veins)

Decrease left ventricular volume

Decrease preload
Decrease workload
Decrease oxygen consumption
Anti  anginal drugs ppt by anjali kotwal
ROUTE OF ADMINISTRATION







1. Sublingual route – rational and effective for the
treatment of acute attacks of angina pectoris. Half-life
depend only on the rate at which they are delivered to
the liver.
2. Oral route – to provide convenient and prolonged
prophylaxis against attacks of angina
3. Intravenous Route – useful in the treatment of
coronary vasospasm and acute ischemic syndrome.
4. Topical route – used to provide gradual absorption
of the drug for prolonged prophylactic purpose.
Drug

Usual single dose

Route of
administration

Duration of action

Short acting
Nitroglycerin

0.15-1.2 mg

sublingual

10 - 30 min

Isosorbide dinitrate

2.5-5 mg

sublingual

10 – 60 min

Amyl nitrite

0.18 – 3 ml

inhalation

3 – 5 min

Long acting
Nitroglycerin sustained
action

6.5 – 13 mg q 6-8 hrs

oral

6 – 8 hrs

Nitroglycerin 2%
ointment

1 – 1.5 inches q hr

topical

3 – 6 hrs

Niroglycerin slow
released

1 –2 mg per 4 hrs

Buccal mucosa

3 – 6 hrs

transdermal

8 –10 hrs

Nitroglycerin
released

slow 10 – 25 mg /24hrs (one
patch/day}

Isosorbide dinitrate

2.5 – 10 mg per 2 hrs

sublingual

1.5 – 2 hrs

Isosorbide dinitrate

10 –60 mg per 4-6 hrs

oral

4 – 6 hrs

Isosorbide dinitrate
chewable

5 – 10 mg per 2-4 hrs

oral

2 – 3 hrs

Isosorbide mononitrate

20 mg per 12 hrs

oral

6 –10 hrs
EFFECTS
1. Coronary artery dilatation
2. Reduction of peripheral arterial resistance
– decrease after load
3. Reduce venous return – decrease preload
PHARMACOKINETICS
The difference between nitrate preparations is
mainly in time of onset of action.
 Nitroglycerin suffers marked 1st pass
metabolism so administration is sublingual.
 t1/2 ~10 minutes.
 Occasionally as nitroglycerin is metabolized
anginal symptoms will return.
 Transdermal administration either as patch or
paste provides a depot of agent for a steady
availability.
 Nitro-Bid is an oral or topical preparation which
saturates the hepatic catabolic pathways
allowing a prolonged level of nitroglycerine.
 Isosorbide mono nitrate & Isosorbide di nitrate
are long acting nitrates that are relatively
resistant to hepatic catabolism ……t1/2 ~ 1
hour.
ADVERSE EFFECTS
1. Throbbing headache
2. Flushing of the face
3. Dizziness – especially at the beginning of
treatment
4. Postural Hypotension – due to pooling of
blood in the dependent portion of the body
CONTRAINDICATIONS
1. Renal ischemia
2. Acute myocardial infarction
3. Patients receiving other antihypertensive
agent
BETA- BLOCKERS
β-Blockers decrease oxygen demands of the
myocardium by lowering the heart rate and
contractility (decrease CO) particularly the
increased demand associated with exercise.
 They also reduce PVR by direct vasodilatations
of both arterial & venous vessels reducing both
pre- and after load.
 These effects are caused by blocking β1
receptors, selective β1 antagonists
(atenolol, metoprolol ) lose their selectivity at
high doses and at least partially block β2
receptors.

β1 antagonists reduce the frequency and
severity of anginal episodes particularly
when used in combination with nitrates.
 β1 antagonists have been shown to improve
survival in post MI patients and decrease the
risk of subsequent cardiac events &
complications.
 There are a number of contraindications for
β blockers: asthma, diabetes, bradycardia,
PVD & COPD.
 β-Blockers in combination with nitrates can
be quite effective

HEMODYNAMIC EFFECT
1. Decrease heart rate
2. Reduced blood pressure and cardiac
contractility without appreciable decrease
in cardiac output
MECHANISM OF ACTION
Decrease heart rate & Contractility
Increase duration of diastole
Decrease workload
Increase coronary blood flow
Decrease
oxy.consumption
Increase oxygen supply
CONTRAINDICATIONS
1. Congestive heart failure
2. Asthma
3. Complete heart block
CALCIUM CHANNEL BLOCKERS


Ca+2 channel blockers protect tissue by inhibiting the
entrance of Ca+2 into cardiac and smooth muscle cells of
the coronary and systemic arterial beds.



All Ca+2 channel blockers produce some vasodilation (↓
PVR) and (-) inotropes.



Some agents also show cardiac conduction particularly
through the AV node thus serving to control cardiac
rhythm.



Some agents have more effect on cardiac muscle than
others but all serve to lower blood pressure.



CHF patients may suffer exacerbation of their failure as
these are (-) inotropes.



They are useful in Prinzmetal angina in conjunction with
nitrates.
AGENTS
Nifedipine:







This Ca+2 channel blocker works mainly on the
arteriolar vasculature decreasing after load it has
minimal effect of conduction or HR.
It is metabolized in the liver and excreted in both the
urine & the feces.
It causes flushing, headache, hypotension and
peripheral edema.
It also has some slowing effect on the GI musculature
resulting in constipation.
A reflex tachycardia associated with the vasodilatation
may elicit myocardial ischemia in tenuous patients, as
such it is generally avoided in non-hypertensive
coronary artery disease.
VERAPAMIL
The agents has its main effect on cardiac
conduction decreasing HR and thereby O2
demand.
 It also has much more (-) inotropic effect than
other Ca+2 channel blockers
 It is a weak vasodilator.
 Because of its focused myocardial effects it is
not used as an antianginal unless there is a
tachyarrhythmia. It is metabolized in the liver.
 It interferes with digoxin levels causing elevated
plasma levels; caution and monitoring of drug
levels are necessary wit concomitant use.

DILTIAZEM
This agent function similarly to Verapamil
however it is more effective against
Prinzmetal angina.
 It has less effect on HR.
 It has similar metabolism and side effects as
Verapamil.

pharmacokinetics
Drugs

Onset of action

Peak of action

Half-life

Nifedipine

20 minutes

1 hour

3-4 hours

Verafamil

1-2 hours

5 hours

8-10 hours

Diltiazem

15 minutes

30 minutes

3-4 hours

Nicardifine

20 minutes

45 minutes

2-4 hours

Felodipine

2-5 hours

6-7 hours

11-16 hour
ADVERSE EFFECT





Nausea and vomiting
Dizziness
Flushing of the face
Tachycardia – due to hypotension
CONTRAINDICATIONS





Cardiogenic shock
Recent myocardial infarction
Heart failure
Atria-ventricular block
COMBINATION THERAPY
1. Nitrates and B-blockers





The additive efficacy is primarily a result of
one drug blocking the adverse effect of the
other agent on net myocardial oxygen
consumption
B-blockers – blocks the reflex tachycardia
associated with nitrates
Nitrates – attenuate the increase in the left
ventricular end diastolic volume associated
with B-lockers by increasing venous
capacitance
CALCIUM CHANNEL BLOCKERS +BETA
BLOCKERS






Useful in the treatment of exertional angina
that is not controlled adequately with
nitrates and B-blockers
B-blockers – attenuate reflex tachycardia
produce by nifedipine
These two drugs produce decrease blood
pressure
CALCIUM CHANNEL
BLOCKER+NITRATES






Useful in severe vasospastic or exertional
angina (particularly in patient with exertional
angina with congestive heart failure and
sick sinus syndrome)
Nitrates reduce preload and after load
Ca channels reduces the after load
Net effect is on reduction of oxygen
demand
TRIPLE DRUGS:-NITRATES+CALCIUM
CHANNEL BLOCKERS+BETA BLOCKER






Useful in patients with exertional angina not
controlled by the administration of two types
of anti-anginal agent
Nifidipine – decrease after load
Nitrates – decrease preload
B-blockers – decrease heart rate &
myocardial contractility
Anti  anginal drugs ppt by anjali kotwal
Presented by:
ANJALI KOTWAL
5TH SEMESTER
B.PHARMACY
SHOOLINI UNIVERSITY

More Related Content

PPT
Anti Arrhythmic Drugs
PPTX
ANTIDIURETICS - a pd presentation
PPTX
Antiarrhythmic drugs
PDF
Anti-Hyperlipidemic Drugs (Pharmacology -II) By- Anshik Srivastava.pdf
PPTX
Antiarrhythmic drugs
PPTX
Hypertension & anti hypertensive drugs
PPSX
Chemistry of Anti Anginal Drugs by Professor Beubenz
PDF
Drugs used for CHF
Anti Arrhythmic Drugs
ANTIDIURETICS - a pd presentation
Antiarrhythmic drugs
Anti-Hyperlipidemic Drugs (Pharmacology -II) By- Anshik Srivastava.pdf
Antiarrhythmic drugs
Hypertension & anti hypertensive drugs
Chemistry of Anti Anginal Drugs by Professor Beubenz
Drugs used for CHF

What's hot (20)

PPT
Antianginal drugs (VK)
PDF
Anti hypertensives and diuretics drugs - pharmacology
PPTX
Antihypertensive drugs naser
PPTX
3rd unit drugs used in congestive heart faliure
PPTX
Arrhythmias
PPTX
Medicinal Chemistry of Diuretics
PPTX
Antihyperlipidemic agents
PPTX
Antiarrhythmic agent
PPTX
3rd unit coagulant and anticoagulant ppt
PPTX
Antidiuretic
PPTX
ARBs USE IN MANAGEMENT OF MYORCARDIAL INFARCTION
PPTX
Antiarrhythmic drugs
PPTX
role of diuretics in the management of congestive heart failure
PPTX
Bradykinin by Raghul Pharmacist
PPTX
Drugs affecting renin-angiotensin system
PPTX
2nd unit diuretics
PPT
18.antihypertensives
PPTX
Pharmacotherapy of hypertension
PPTX
2nd unit anti-anginal agents
Antianginal drugs (VK)
Anti hypertensives and diuretics drugs - pharmacology
Antihypertensive drugs naser
3rd unit drugs used in congestive heart faliure
Arrhythmias
Medicinal Chemistry of Diuretics
Antihyperlipidemic agents
Antiarrhythmic agent
3rd unit coagulant and anticoagulant ppt
Antidiuretic
ARBs USE IN MANAGEMENT OF MYORCARDIAL INFARCTION
Antiarrhythmic drugs
role of diuretics in the management of congestive heart failure
Bradykinin by Raghul Pharmacist
Drugs affecting renin-angiotensin system
2nd unit diuretics
18.antihypertensives
Pharmacotherapy of hypertension
2nd unit anti-anginal agents
Ad

Viewers also liked (20)

PPT
Pharmacological screening of anti arrhythmic drugs 3
PPT
Evaluation of antianginal drugs
PPT
Screening of drugs used in MI
PPTX
Hepatoprotective agents
PPT
Dyslipidemia
PPTX
Cyanosis
PDF
Nursing care of client with Coronary artery disease part 2 of 2
PPTX
Aortic regurgitation
PPTX
Ventricular septal defect (vsd)
PPTX
Raynaud's phenomenon
PPT
Peripheral Vascular Examination
PPTX
Unstable Angina Pectoris
PPTX
Mitral stenosis
PPTX
Eisenmenger syndrome
PPTX
Acute pericarditis
PPTX
Pericardial effusion
PPT
Management Of PDA
PPT
TRANS ESOPHAGEAL ECHOCARDIOGRAPHY
Pharmacological screening of anti arrhythmic drugs 3
Evaluation of antianginal drugs
Screening of drugs used in MI
Hepatoprotective agents
Dyslipidemia
Cyanosis
Nursing care of client with Coronary artery disease part 2 of 2
Aortic regurgitation
Ventricular septal defect (vsd)
Raynaud's phenomenon
Peripheral Vascular Examination
Unstable Angina Pectoris
Mitral stenosis
Eisenmenger syndrome
Acute pericarditis
Pericardial effusion
Management Of PDA
TRANS ESOPHAGEAL ECHOCARDIOGRAPHY
Ad

Similar to Anti anginal drugs ppt by anjali kotwal (20)

PPTX
Antianginals - pharmacology
PPTX
Pharma seminar new version
PPT
Antianginal Drugs
PPT
Antianginal Drugs
PPT
Antianginal Drugs a
PPT
Antianginal Drugs
PPTX
Antianginal drugs
PPT
angina ppt.ppt
PPTX
Antianginals
PPT
Antianginals +Calcium channel blockers AHS gowtham sap
PPTX
Antianginal
PPT
2nd year anti-anginal_drugs
PPTX
Anti-Anginal Drugs.pptx Cardiac Pharmacology
PPTX
Anti Anginal hjk bhjkmhjkkmkkkDrugs.pptx
PPT
Anti-Anginal drugs
PPT
Anti-Angina & Anti arryhthias Drugs Group Two.ppt
PPT
Lecture 10_Angina_Dyslipidemia, pharmacology.ppt
PPTX
Anti Anginal Drugs and its side affect and uses
PDF
Angina drugs used
Antianginals - pharmacology
Pharma seminar new version
Antianginal Drugs
Antianginal Drugs
Antianginal Drugs a
Antianginal Drugs
Antianginal drugs
angina ppt.ppt
Antianginals
Antianginals +Calcium channel blockers AHS gowtham sap
Antianginal
2nd year anti-anginal_drugs
Anti-Anginal Drugs.pptx Cardiac Pharmacology
Anti Anginal hjk bhjkmhjkkmkkkDrugs.pptx
Anti-Anginal drugs
Anti-Angina & Anti arryhthias Drugs Group Two.ppt
Lecture 10_Angina_Dyslipidemia, pharmacology.ppt
Anti Anginal Drugs and its side affect and uses
Angina drugs used

Recently uploaded (20)

PPTX
Post Op complications in general surgery
PDF
OSCE SERIES ( Questions & Answers ) - Set 3.pdf
PPT
Opthalmology presentation MRCP preparation.ppt
PPTX
thio and propofol mechanism and uses.pptx
PDF
Adverse drug reaction and classification
PPTX
@K. CLINICAL TRIAL(NEW DRUG DISCOVERY)- KIRTI BHALALA.pptx
PPTX
Impression Materials in dental materials.pptx
PDF
OSCE SERIES ( Questions & Answers ) - Set 5.pdf
PPT
nephrology MRCP - Member of Royal College of Physicians ppt
PPTX
HYPERSENSITIVITY REACTIONS - Pathophysiology Notes for Second Year Pharm D St...
PDF
Impact of Technology on Patient Autonomy (www.kiu.ac.ug)
PPTX
Vesico ureteric reflux.. Introduction and clinical management
PPT
Infections Member of Royal College of Physicians.ppt
PDF
Forensic Psychology and Its Impact on the Legal System.pdf
PDF
MNEMONICS MNEMONICS MNEMONICS MNEMONICS s
PPTX
Hypertensive disorders in pregnancy.pptx
PPTX
Wheat allergies and Disease in gastroenterology
PPTX
ARTHRITIS and Types,causes,pathophysiology,clinicalanifestations,diagnostic e...
PPTX
Neoplasia III.pptxjhghgjhfj fjfhgfgdfdfsrbvhv
PPTX
Critical Issues in Periodontal Research- An overview
Post Op complications in general surgery
OSCE SERIES ( Questions & Answers ) - Set 3.pdf
Opthalmology presentation MRCP preparation.ppt
thio and propofol mechanism and uses.pptx
Adverse drug reaction and classification
@K. CLINICAL TRIAL(NEW DRUG DISCOVERY)- KIRTI BHALALA.pptx
Impression Materials in dental materials.pptx
OSCE SERIES ( Questions & Answers ) - Set 5.pdf
nephrology MRCP - Member of Royal College of Physicians ppt
HYPERSENSITIVITY REACTIONS - Pathophysiology Notes for Second Year Pharm D St...
Impact of Technology on Patient Autonomy (www.kiu.ac.ug)
Vesico ureteric reflux.. Introduction and clinical management
Infections Member of Royal College of Physicians.ppt
Forensic Psychology and Its Impact on the Legal System.pdf
MNEMONICS MNEMONICS MNEMONICS MNEMONICS s
Hypertensive disorders in pregnancy.pptx
Wheat allergies and Disease in gastroenterology
ARTHRITIS and Types,causes,pathophysiology,clinicalanifestations,diagnostic e...
Neoplasia III.pptxjhghgjhfj fjfhgfgdfdfsrbvhv
Critical Issues in Periodontal Research- An overview

Anti anginal drugs ppt by anjali kotwal

  • 2. Anti anginal drugs  Angina pectoris  Types  Classification  Nitrates  Calcium channel blockers  blockers  Combination therapy  CONTENT
  • 3. ANTI-ANGINAL DRUGS     Antianginal drugs may relieve attacks of acute myocardial ischemia by increasing myocardial oxygen supply or by decreasing myocardial oxygen demand Three groups of pharmacological agents have been shown to be effective in reducing the frequency, severity, or both of primary or secondary angina. These agents include the nitrates, adrenoceptor antagonists, and calcium entry blockers. To understand the beneficial actions of these agents, it is important to be familiar with the major factors regulating the balance between
  • 4. ANGINA PECTORIS It is the principal symptoms of patient with ischemic heart disease.  Manifested by sudden, severe, pressing substernal pain that often radiates to the left shoulder and along the flexor surface of the left arm.  Usually precipitated by exercise, excitement or a heavy meal. 
  • 6. TYPES OF ANGINA PECTORIS
  • 10. NITRATES Classification of nitrates: 1. Rapidly acting nitrates * used to terminate acute attack of angina * e.g.- Nitroglycerin and Amyl nitrate * usually administered sublingually 2. Long acting nitrates * used to prevent an attack of angina * e.g. – tetra nitrate, Iso sorbide di nitrate, Penta erythrytol tetra nitrate * administered orally or topically
  • 11.     Organic nitrates & nitrites are simple nitric & nitrous esters of glycerol. These agents cause a rapid decrease in myocardial oxygen demand leading to rapid resolution of symptoms. Nitrates are effective for all types of angina. Activation of guanylate cyclase increases cGMP activating a cGMP kinase leading to dephosphorylation of myosin light chains decreasing contractile force. ORGANIC NITRATES
  • 13. 1ST MECHANISM OF ACTION Coronary artery dilatation Decrease coronary bed resistance (Relieved coronary vasospasm) Increase coronary blood flow Increase oxygen supply
  • 14. 2ND MECHANISM OF ACTION Reduction on peripheral resistance (Secondary to dilatation of aorta) Decrease blood pressure Decrease after load Decrease workload Decrease oxygen consumption
  • 15. 3RD MECHANISM OF ACTION Reduced venous return (Due to dilatation of the veins) Decrease left ventricular volume Decrease preload Decrease workload Decrease oxygen consumption
  • 17. ROUTE OF ADMINISTRATION     1. Sublingual route – rational and effective for the treatment of acute attacks of angina pectoris. Half-life depend only on the rate at which they are delivered to the liver. 2. Oral route – to provide convenient and prolonged prophylaxis against attacks of angina 3. Intravenous Route – useful in the treatment of coronary vasospasm and acute ischemic syndrome. 4. Topical route – used to provide gradual absorption of the drug for prolonged prophylactic purpose.
  • 18. Drug Usual single dose Route of administration Duration of action Short acting Nitroglycerin 0.15-1.2 mg sublingual 10 - 30 min Isosorbide dinitrate 2.5-5 mg sublingual 10 – 60 min Amyl nitrite 0.18 – 3 ml inhalation 3 – 5 min Long acting Nitroglycerin sustained action 6.5 – 13 mg q 6-8 hrs oral 6 – 8 hrs Nitroglycerin 2% ointment 1 – 1.5 inches q hr topical 3 – 6 hrs Niroglycerin slow released 1 –2 mg per 4 hrs Buccal mucosa 3 – 6 hrs transdermal 8 –10 hrs Nitroglycerin released slow 10 – 25 mg /24hrs (one patch/day} Isosorbide dinitrate 2.5 – 10 mg per 2 hrs sublingual 1.5 – 2 hrs Isosorbide dinitrate 10 –60 mg per 4-6 hrs oral 4 – 6 hrs Isosorbide dinitrate chewable 5 – 10 mg per 2-4 hrs oral 2 – 3 hrs Isosorbide mononitrate 20 mg per 12 hrs oral 6 –10 hrs
  • 19. EFFECTS 1. Coronary artery dilatation 2. Reduction of peripheral arterial resistance – decrease after load 3. Reduce venous return – decrease preload
  • 20. PHARMACOKINETICS The difference between nitrate preparations is mainly in time of onset of action.  Nitroglycerin suffers marked 1st pass metabolism so administration is sublingual.  t1/2 ~10 minutes.  Occasionally as nitroglycerin is metabolized anginal symptoms will return.  Transdermal administration either as patch or paste provides a depot of agent for a steady availability.  Nitro-Bid is an oral or topical preparation which saturates the hepatic catabolic pathways allowing a prolonged level of nitroglycerine.  Isosorbide mono nitrate & Isosorbide di nitrate are long acting nitrates that are relatively resistant to hepatic catabolism ……t1/2 ~ 1 hour.
  • 21. ADVERSE EFFECTS 1. Throbbing headache 2. Flushing of the face 3. Dizziness – especially at the beginning of treatment 4. Postural Hypotension – due to pooling of blood in the dependent portion of the body
  • 22. CONTRAINDICATIONS 1. Renal ischemia 2. Acute myocardial infarction 3. Patients receiving other antihypertensive agent
  • 23. BETA- BLOCKERS β-Blockers decrease oxygen demands of the myocardium by lowering the heart rate and contractility (decrease CO) particularly the increased demand associated with exercise.  They also reduce PVR by direct vasodilatations of both arterial & venous vessels reducing both pre- and after load.  These effects are caused by blocking β1 receptors, selective β1 antagonists (atenolol, metoprolol ) lose their selectivity at high doses and at least partially block β2 receptors. 
  • 24. β1 antagonists reduce the frequency and severity of anginal episodes particularly when used in combination with nitrates.  β1 antagonists have been shown to improve survival in post MI patients and decrease the risk of subsequent cardiac events & complications.  There are a number of contraindications for β blockers: asthma, diabetes, bradycardia, PVD & COPD.  β-Blockers in combination with nitrates can be quite effective 
  • 25. HEMODYNAMIC EFFECT 1. Decrease heart rate 2. Reduced blood pressure and cardiac contractility without appreciable decrease in cardiac output
  • 26. MECHANISM OF ACTION Decrease heart rate & Contractility Increase duration of diastole Decrease workload Increase coronary blood flow Decrease oxy.consumption Increase oxygen supply
  • 27. CONTRAINDICATIONS 1. Congestive heart failure 2. Asthma 3. Complete heart block
  • 28. CALCIUM CHANNEL BLOCKERS  Ca+2 channel blockers protect tissue by inhibiting the entrance of Ca+2 into cardiac and smooth muscle cells of the coronary and systemic arterial beds.  All Ca+2 channel blockers produce some vasodilation (↓ PVR) and (-) inotropes.  Some agents also show cardiac conduction particularly through the AV node thus serving to control cardiac rhythm.  Some agents have more effect on cardiac muscle than others but all serve to lower blood pressure.  CHF patients may suffer exacerbation of their failure as these are (-) inotropes.  They are useful in Prinzmetal angina in conjunction with nitrates.
  • 29. AGENTS Nifedipine:      This Ca+2 channel blocker works mainly on the arteriolar vasculature decreasing after load it has minimal effect of conduction or HR. It is metabolized in the liver and excreted in both the urine & the feces. It causes flushing, headache, hypotension and peripheral edema. It also has some slowing effect on the GI musculature resulting in constipation. A reflex tachycardia associated with the vasodilatation may elicit myocardial ischemia in tenuous patients, as such it is generally avoided in non-hypertensive coronary artery disease.
  • 30. VERAPAMIL The agents has its main effect on cardiac conduction decreasing HR and thereby O2 demand.  It also has much more (-) inotropic effect than other Ca+2 channel blockers  It is a weak vasodilator.  Because of its focused myocardial effects it is not used as an antianginal unless there is a tachyarrhythmia. It is metabolized in the liver.  It interferes with digoxin levels causing elevated plasma levels; caution and monitoring of drug levels are necessary wit concomitant use. 
  • 31. DILTIAZEM This agent function similarly to Verapamil however it is more effective against Prinzmetal angina.  It has less effect on HR.  It has similar metabolism and side effects as Verapamil. 
  • 32. pharmacokinetics Drugs Onset of action Peak of action Half-life Nifedipine 20 minutes 1 hour 3-4 hours Verafamil 1-2 hours 5 hours 8-10 hours Diltiazem 15 minutes 30 minutes 3-4 hours Nicardifine 20 minutes 45 minutes 2-4 hours Felodipine 2-5 hours 6-7 hours 11-16 hour
  • 33. ADVERSE EFFECT     Nausea and vomiting Dizziness Flushing of the face Tachycardia – due to hypotension
  • 34. CONTRAINDICATIONS     Cardiogenic shock Recent myocardial infarction Heart failure Atria-ventricular block
  • 35. COMBINATION THERAPY 1. Nitrates and B-blockers    The additive efficacy is primarily a result of one drug blocking the adverse effect of the other agent on net myocardial oxygen consumption B-blockers – blocks the reflex tachycardia associated with nitrates Nitrates – attenuate the increase in the left ventricular end diastolic volume associated with B-lockers by increasing venous capacitance
  • 36. CALCIUM CHANNEL BLOCKERS +BETA BLOCKERS    Useful in the treatment of exertional angina that is not controlled adequately with nitrates and B-blockers B-blockers – attenuate reflex tachycardia produce by nifedipine These two drugs produce decrease blood pressure
  • 37. CALCIUM CHANNEL BLOCKER+NITRATES     Useful in severe vasospastic or exertional angina (particularly in patient with exertional angina with congestive heart failure and sick sinus syndrome) Nitrates reduce preload and after load Ca channels reduces the after load Net effect is on reduction of oxygen demand
  • 38. TRIPLE DRUGS:-NITRATES+CALCIUM CHANNEL BLOCKERS+BETA BLOCKER     Useful in patients with exertional angina not controlled by the administration of two types of anti-anginal agent Nifidipine – decrease after load Nitrates – decrease preload B-blockers – decrease heart rate & myocardial contractility
  • 40. Presented by: ANJALI KOTWAL 5TH SEMESTER B.PHARMACY SHOOLINI UNIVERSITY